Efficacy and safety of immune checkpoint inhibitors plus anlotinib in small cell lung cancer with brain metastases: a retrospective, multicentre study

[1] Rudin CM(2021)Small-cell lung cancer Nat Rev Dis Primers 7 3-3408

[2] Brambilla E(2020)Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases JAMA ONCOL 6 1028-638

[3] Faivre-Finn C(2000)Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy—A phase III study of the european organization for the research and treatment of cancer lung cancer cooperative group J CLIN ONCOL 18 3400-630

[4] Sage J(2021)Treatment and prevention of brain metastases in small cell lung cancer Am J Clin Oncol 44 629-65

[5] Rusthoven CG(2021)updated overall survival and pd-l1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133) J Clin Oncol 39 619-2379

[6] Yamamoto M(2021)Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Lancet Oncol 22 51-1219

[7] Bernhardt D(2020)Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study J Clin Oncol 38 2369-S824

[8] Postmus PE(2018)Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor Cancer Sci 109 1207-2532

[9] Haaxma-Reiche H(2019)P2.12-26 the impact of anlotinib for relapsed sclc patients with brain metastases: a subgroup analysis of ALTER 1202 J Thorac Oncol 14 S823-29

[10] Smit EF(2020)anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells CELL DEATH DIS 11 309-341

[1] Rudin CM(2021)Small-cell lung cancer Nat Rev Dis Primers 7 3-3408

[2] Brambilla E(2020)Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases JAMA ONCOL 6 1028-638

[3] Faivre-Finn C(2000)Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy—A phase III study of the european organization for the research and treatment of cancer lung cancer cooperative group J CLIN ONCOL 18 3400-630

[4] Sage J(2021)Treatment and prevention of brain metastases in small cell lung cancer Am J Clin Oncol 44 629-65

[5] Rusthoven CG(2021)updated overall survival and pd-l1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133) J Clin Oncol 39 619-2379

[6] Yamamoto M(2021)Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Lancet Oncol 22 51-1219

[7] Bernhardt D(2020)Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study J Clin Oncol 38 2369-S824

[8] Postmus PE(2018)Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor Cancer Sci 109 1207-2532

[9] Haaxma-Reiche H(2019)P2.12-26 the impact of anlotinib for relapsed sclc patients with brain metastases: a subgroup analysis of ALTER 1202 J Thorac Oncol 14 S823-29

[10] Smit EF(2020)anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells CELL DEATH DIS 11 309-341